Roth Capital Reduces Earnings Estimates for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Stock analysts at Roth Capital dropped their Q2 2025 earnings estimates for shares of Zimmer Biomet in a note issued to investors on Tuesday, May 6th. Roth Capital analyst J. Wittes now anticipates that the medical equipment provider will post earnings per share of $1.79 for the quarter, down from their previous forecast of $2.04. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Roth Capital also issued estimates for Zimmer Biomet’s Q3 2025 earnings at $1.90 EPS, Q4 2025 earnings at $2.29 EPS, FY2025 earnings at $7.90 EPS, Q1 2026 earnings at $1.81 EPS, Q2 2026 earnings at $2.13 EPS, Q3 2026 earnings at $1.93 EPS, Q4 2026 earnings at $2.47 EPS and FY2026 earnings at $8.34 EPS.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $1.91 billion for the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The business’s revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.94 earnings per share.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. reduced their price target on shares of Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating for the company in a research report on Tuesday. JMP Securities reduced their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating for the company in a report on Wednesday. Royal Bank of Canada dropped their price target on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a research report on Tuesday. BTIG Research reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Finally, Wells Fargo & Company dropped their target price on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating on the stock in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $114.15.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $95.22 on Thursday. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock has a market cap of $18.84 billion, a P/E ratio of 21.40, a P/E/G ratio of 1.95 and a beta of 0.78. The stock has a 50 day moving average of $104.43 and a two-hundred day moving average of $106.11. Zimmer Biomet has a twelve month low of $89.92 and a twelve month high of $122.25.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were given a dividend of $0.24 per share. The ex-dividend date was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.01%. Zimmer Biomet’s payout ratio is 21.24%.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 1.39% of the company’s stock.

Institutional Trading of Zimmer Biomet

A number of hedge funds have recently bought and sold shares of ZBH. CKW Financial Group raised its position in shares of Zimmer Biomet by 11.7% in the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 100 shares in the last quarter. Romano Brothers AND Company raised its holdings in Zimmer Biomet by 1.1% in the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after acquiring an additional 102 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its stake in Zimmer Biomet by 2.3% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider’s stock valued at $485,000 after acquiring an additional 102 shares during the last quarter. M&T Bank Corp grew its holdings in Zimmer Biomet by 0.4% during the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider’s stock worth $2,834,000 after acquiring an additional 108 shares in the last quarter. Finally, MGO One Seven LLC increased its position in shares of Zimmer Biomet by 5.1% in the 4th quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 110 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.